Oncology PopPKExposure-response

Pertuzumab neoadjuvant population PK

Reference paper ↗

A two-compartment population PK model connecting pertuzumab dosing and lean-body-weight and albumin covariates to concentration and cumulative exposure during neoadjuvant therapy.

Therapeutic
Pertuzumab
Modality
Monoclonal antibody
Target
HER2 / ERBB2
Disease
HER2-positive early breast cancer
Model type
PopPK, Exposure-response

Complete model workspace

Checking workspace access…

Parameters
12
States
4
Equations
4
Derived outputs
20

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Typical NeoSphere 840/420 mg every 3 weeks four-cycle PK shell

How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure? Explore this intervention regimen through Pertuzumab concentration, Cumulative pertuzumab exposure, Covariate-adjusted clearance, Covariate-adjusted central volume.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–84 day; step 1

InputDefaultAvailable range
Systemic clearance0.235 L/day0.1175–0.3525 L/day
Central distribution volume3.11 L1.555–4.665 L
Intercompartmental clearance0.534 L/day0.267–0.801 L/day
Peripheral distribution volume2.46 L1.23–3.69 L
Lean body weight44.6 kg22.3–66.9 kg

Expected readouts

Pertuzumab concentration · Exposure (AUC) (ug*day/mL) · Covariate adjusted clearance · Covariate adjusted central volume

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 12 declared model parameters.

More key parameters (1)

How the model represents the biology

A two-compartment population PK model connecting pertuzumab dosing and lean-body-weight and albumin covariates to concentration and cumulative exposure during neoadjuvant therapy.

How do lean body weight and albumin alter pertuzumab disposition?Intravenous pertuzumab enters a central pool, exchanges with a peripheral pool, undergoes covariate-adjusted clearance, and accumulates central exposure. Lean body weight scales clearance and both distribution volumes, while albumin scales clearance only.BIOLOGY OVERVIEWHow do lean body weight and albumin alter pertuzumab disposition?IV pertuzumabInfusion to central amountCentral exposurePertuzumab concentrationPeripheral poolReversible distributionPertuzumab clearanceCovariate-adjusted lossLean body weightScales CL, Vc and VpAlbuminScales clearance onlySystemic exposureConcentration and cumulativeAUCPRIMARY READOUTSPertuzumab concentrationPertuzumab concentrationCumulative exposureCumulative exposureCovariate-adjusted clearanceCovariate-adjusted clearan…Central volumeCentral volume

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: HER2 binding, receptor occupancy, tumor-cell killing, pathological complete response, and any exposure-response relationship are not present; this released dynamic model is PK-only.

Modeled relationships (8)
  • IV pertuzumab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → Pertuzumab clearance: systemic CL (loss)
  • Lean body weight → Pertuzumab clearance: LBW scales CL (modulation)
  • Lean body weight → Central exposure: LBW scales Vc (modulation)
  • Lean body weight → Peripheral pool: LBW scales Vp (modulation)
  • Albumin → Pertuzumab clearance: albumin scales CL (modulation)
  • Central exposure → Systemic exposure: integrates C (production)

Modeled relationships: IV pertuzumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Pertuzumab clearance: systemic CL (loss); Lean body weight to Pertuzumab clearance: LBW scales CL (modulation); Lean body weight to Central exposure: LBW scales Vc (modulation); Lean body weight to Peripheral pool: LBW scales Vp (modulation); Albumin to Pertuzumab clearance: albumin scales CL (modulation); Central exposure to Systemic exposure: integrates C (production).

Primary readouts: Pertuzumab concentration; Cumulative exposure; Covariate-adjusted clearance; Central volume.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID quartino_2017_pertuzumab_neoadjuvant_pk_er.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics